---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-034355"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2022-12-02T23:59:59+00:00"
generated_at: "2026-06-21T10:21:56.917979+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lucid Diagnostics issues 3.38M shares to parent PAVmed for services, expense reimbursement, and acquisition

## Summary
- PAVmed elected stock for $1.65M in MSA fees (July-Sept 2022): 750,818 shares at 0.70 floor.
- New PBERA formalizes expense reimbursement; PAVmed received 1,479,326 shares for $2.72M in accrued payroll/benefits.
- CapNostics assignment settled with 1,145,086 shares to PAVmed, covering the ~$2.1M purchase price.
- Total issuance of 3,375,230 unregistered shares to parent under Section 4(a)(2) exemptions.

## SEC filing metadata
- accession: 0001493152-22-034355
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2022-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315222034355/0001493152-22-034355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315222034355/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-034355
- JSON: https://secwatch.observer/filing/0001493152-22-034355.json
- Plain text: https://secwatch.observer/filing/0001493152-22-034355.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.